| Symbol | LGVN |
|---|---|
| Name | LONGEVERON INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1951 NW 7TH AVENUE,SUITE 520, MIAMI, Florida, 33136, United States |
| Telephone | +1 305 909-0840 |
| Fax | — |
| — | |
| Website | https://www.longeveron.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001721484 |
| Description | Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimers disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Additional info from NASDAQ: |
Longeveron - New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
Read moreNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
Read moreLongeveron - Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Read moreLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Read moreLongeveron - Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Read moreLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Read moreNew Form DEFA14A - Longeveron Inc. <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001213900-26-059530 <b>Size:</b> 2 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02587572 | Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SI… | Phase2 | Metabolic Disease | Withdrawn | 2023-12-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05233774 | Lomecel-B Effects on Alzheimer's Disease | Phase2 | Mild Alzheimer's Disease | Completed | 2021-12-28 | 2023-09-29 | ClinicalTrials.gov |
| NCT04925024 | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Synd… | Phase2 | Hypoplastic Left Heart Syndrome | Active_Not_Recruiting | 2021-06-25 | 2026-08-31 | ClinicalTrials.gov |
| NCT04629105 | Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOV… | Phase1 | ARDS, Human | Unknown | 2020-07-24 | 2025-07-01 | ClinicalTrials.gov |
| NCT03525418 | Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome… | Phase1 | HLHS | Unknown | 2018-02-21 | 2025-12-31 | ClinicalTrials.gov |
| NCT03169231 | Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Fr… | Phase2 | Aging Frailty | Completed | 2017-07-06 | 2021-09-30 | ClinicalTrials.gov |
| NCT02982915 | Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty | Phase1 | Aging Frailty | Completed | 2016-11-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT02600130 | Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease | Phase1 | Alzheimer's Disease | Completed | 2016-10-10 | 2021-09-01 | ClinicalTrials.gov |
| NCT02398604 | Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome | Phase1 | Hypoplastic Left Heart Syndrome | Terminated | 2015-04-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02065245 | AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy V… | Phase1 | Frailty | Completed | 2014-03-03 | 2020-10-02 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Other | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Placebo | Other | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Other | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Placebo | Other | Phase PHASE1 | Hypoplastic Left Heart Syndrome | TERMINATED | NCT02398604 |
| Allo-hMSCs | Other | Phase PHASE1 | Hypoplastic Left Heart Syndrome | TERMINATED | NCT02398604 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02600130 |
| Longeveron Mesenchymal Stem Cells | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02600130 |
| Placebo | Other | Phase PHASE2 | Aging Frailty | COMPLETED | NCT03169231 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Other | Phase PHASE2 | Aging Frailty | COMPLETED | NCT03169231 |
| Fluzone High Dose Vaccine | Other | Phase PHASE1 | Aging Frailty | COMPLETED | NCT02982915 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Other | Phase PHASE1 | Aging Frailty | COMPLETED | NCT02982915 |
| Peripheral Intravenous (IV) infusion of LMSCs | Other | Phase PHASE2 | Metabolic Disease | WITHDRAWN | NCT02587572 |
| Longeveron Mesenchymal Stem Cells | Other | Phase PHASE1 | HLHS | UNKNOWN | NCT03525418 |
| Placebo | Other | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Allogeneic MSC | Other | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Placebo | Other | Phase PHASE1 | ARDS, Human | UNKNOWN | NCT04629105 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Other | Phase PHASE1 | ARDS, Human | UNKNOWN | NCT04629105 |
| Lomecel-B medicinal signaling cells | Other | Phase PHASE2 | Hypoplastic Left Heart Syndrome | ACTIVE_NOT_RECRUITING | NCT04925024 |
| Allogeneic MSC | DRUG | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Lomecel-B medicinal signaling cells | BIOLOGICAL | Phase PHASE2 | Hypoplastic Left Heart Syndrome | ACTIVE_NOT_RECRUITING | NCT04925024 |
| Fluzone High Dose Vaccine | BIOLOGICAL | Phase PHASE1 | Aging Frailty | COMPLETED | NCT02982915 |
| Longeveron Mesenchymal Stem Cells (LMSCs) | BIOLOGICAL | Phase PHASE1 | ARDS, Human | ACTIVE_NOT_RECRUITING | NCT04629105 |
| Longeveron Mesenchymal Stem Cells | BIOLOGICAL | Phase PHASE1 | HLHS | ACTIVE_NOT_RECRUITING | NCT03525418 |
| Peripheral Intravenous (IV) infusion of LMSCs | BIOLOGICAL | Phase PHASE2 | Metabolic Disease | WITHDRAWN | NCT02587572 |
| Allo-hMSCs | DRUG | Phase PHASE1 | Hypoplastic Left Heart Syndrome | TERMINATED | NCT02398604 |
| Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | BIOLOGICAL | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |
| Placebo | OTHER | Phase PHASE2 | Mild Alzheimer's Disease | COMPLETED | NCT05233774 |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | BIOLOGICAL | Phase PHASE1 | Frailty | COMPLETED | NCT02065245 |